Šimičević, L.; Slišković, A.M.; Kirhmajer, M.V.; Ganoci, L.; Holik, H.; Palić, J.; Samardžić, J.; Božina, T.
Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series. Pharmacy 2023, 11, 29.
https://doi.org/10.3390/pharmacy11010029
AMA Style
Šimičević L, Slišković AM, Kirhmajer MV, Ganoci L, Holik H, Palić J, Samardžić J, Božina T.
Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series. Pharmacy. 2023; 11(1):29.
https://doi.org/10.3390/pharmacy11010029
Chicago/Turabian Style
Šimičević, Livija, Ana Marija Slišković, Majda Vrkić Kirhmajer, Lana Ganoci, Hrvoje Holik, Jozefina Palić, Jure Samardžić, and Tamara Božina.
2023. "Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series" Pharmacy 11, no. 1: 29.
https://doi.org/10.3390/pharmacy11010029
APA Style
Šimičević, L., Slišković, A. M., Kirhmajer, M. V., Ganoci, L., Holik, H., Palić, J., Samardžić, J., & Božina, T.
(2023). Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series. Pharmacy, 11(1), 29.
https://doi.org/10.3390/pharmacy11010029